نتائج البحث

Guillain-Barré Syndrome in a Patient Receiving Anti-Tumor Necrosis Factor for Crohn Disease: Coincidence or Consequence?

• Authors : Ferreira SDC; Division of Gastroenterology, Department of Medicine, Hospital das Clínicas, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.; Vasconcelos JRO

Subjects: Guillain-Barre Syndrome*/Guillain-Barre Syndrome*/Guillain-Barre Syndrome*/chemically induced ; Guillain-Barre Syndrome*/Guillain-Barre Syndrome*/Guillain-Barre Syndrome*/diagnosis ; Crohn Disease*/Crohn Disease*/Crohn Disease*/drug therapy

• Source: The American journal of case reports [Am J Case Rep] 2024 Jun 02; Vol. 25, pp. e943709. Date of Electronic Publication: 2024 Jun 02.Publisher: International Scientific Information, Inc Country of Publication: United States NLM ID: 101489566 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Response to the Second TNF-α Inhibitor (Adalimumab or Infliximab) after Failing the First One in Refractory Idiopathic Inflammatory Retinal Vascular Leakage.

• Authors : Maleki A; Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts, USA.; The Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts, USA.

Subjects: Tumor Necrosis Factor Inhibitors* ; Tumor Necrosis Factor-alpha*; Adalimumab/Adalimumab/Adalimumab/therapeutic use

• Source: Ocular immunology and inflammation [Ocul Immunol Inflamm] 2022 Jul; Vol. 30 (5), pp. 1099-1108. Date of Electronic Publication: 2021 Mar 01.Publisher: Informa Healthcare Country of Publication: England NLM ID: 9312169 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review.

• Authors : Huang W; Department of Geriatric Medicine and Gastroenterology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.; Zhang X

Subjects: Tumor Necrosis Factor-alpha*/Tumor Necrosis Factor-alpha*/Tumor Necrosis Factor-alpha*/antagonists & inhibitors ; Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/drug therapy ; Pregnancy Complications*/Pregnancy Complications*/Pregnancy Complications*/drug therapy

• Source: BMC pregnancy and childbirth [BMC Pregnancy Childbirth] 2024 Apr 08; Vol. 24 (1), pp. 251. Date of Electronic Publication: 2024 Apr 08.Publisher: BioMed Central Country of Publication: England NLM ID: 100967799 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2393

تفاصيل العنوان

An in vitro study elucidating the synergistic effects of aqueous cinnamon extract and an anti-TNF-α biotherapeutic: implications for a complementary and alternative therapy for non-responders.

• Authors : Khedkar S; Department of Biochemistry, School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar, 144411, Punjab, India.; Khan MA

Subjects: Tumor Necrosis Factor-alpha* ; Complementary Therapies*; Humans

• Source: BMC complementary medicine and therapies [BMC Complement Med Ther] 2024 Mar 23; Vol. 24 (1), pp. 131. Date of Electronic Publication: 2024 Mar 23.Publisher: BioMed Central Country of Publication: England NLM ID: 101761232 Publication Model: Electronic Cited Medium: Internet ISSN: 2662-7671

تفاصيل العنوان

Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN).

• Authors : Jae Hee Cheon¹ ; Hyun-Soo Kim²; Dong Soo Han³

• Source: Gut & Liver. Sep2023, Vol. 17 Issue 5, p777-785. 9p.

تفاصيل العنوان

Preconcentration and SERS-based determination of infliximab in blood by using a TNF-α-modified gold-coated copper oxide nanomaterial.

• Authors : Muneer S; Molecular Design and Synthesis Discipline, Science and Engineering Faculty, Queensland University of Technology, 2 George Street, Brisbane, QLD, 4000, Australia.; Discipline of Environmental Technologies, Science and Engineering Faculty, Queensland University of Technology, 2 George Street, Brisbane, QLD, 4000, Australia.

Subjects: Infliximab/Infliximab/Infliximab/*blood ; Metal Nanoparticles/Metal Nanoparticles/Metal Nanoparticles/*chemistry ; Spectrum Analysis, Raman/Spectrum Analysis, Raman/Spectrum Analysis, Raman/*methods

• Source: Mikrochimica acta [Mikrochim Acta] 2019 Nov 15; Vol. 186 (12), pp. 780. Date of Electronic Publication: 2019 Nov 15.Publisher: Springer-Verlag Country of Publication: Austria NLM ID: 7808782 Publication Model: Electronic Cited Medium: Internet ISSN: 1436-5073

تفاصيل العنوان

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.

• Authors : Herrmann O; Department of Hematology Oncology Hemostaseology and Stem Cell Transplantation Faculty of Medicine, University Hospital RWTH Aachen, Pauwelsstr 30, 52074, Aachen, Germany.; Kuepper MK

Subjects: Anti-Inflammatory Agents/Anti-Inflammatory Agents/Anti-Inflammatory Agents/*therapeutic use ; Infliximab/Infliximab/Infliximab/*therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/Leukemia, Myelogenous, Chronic, BCR-ABL Positive/Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy

• Source: BMC cancer [BMC Cancer] 2019 Jul 04; Vol. 19 (1), pp. 658. Date of Electronic Publication: 2019 Jul 04.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.

• Authors : Feagan BG; Robarts Research Institute, Western University, London, ON, Canada.; Lam G

Subjects: Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/*administration & dosage ; Infliximab/Infliximab/Infliximab/*administration & dosage ; Tumor Necrosis Factor-alpha/Tumor Necrosis Factor-alpha/Tumor Necrosis Factor-alpha/*antagonists & inhibitors

• Source: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2019 Jan; Vol. 49 (1), pp. 31-40. Date of Electronic Publication: 2018 Nov 08.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

[Peripheral neuropathy during Infliximab therapy: a case study].

• Authors : Zinebi A; Service de Médecine Interne Hôpital Militaire Moulay Ismail I, Meknès, Maroc.; Akhouad Y

Subjects: Gastrointestinal Agents/Gastrointestinal Agents/Gastrointestinal Agents/*adverse effects ; Infliximab/Infliximab/Infliximab/*adverse effects ; Peripheral Nervous System Diseases/Peripheral Nervous System Diseases/Peripheral Nervous System Diseases/*chemically induced

• Source: The Pan African medical journal [Pan Afr Med J] 2016 Jul 27; Vol. 24, pp. 271. Date of Electronic Publication: 2016 Jul 27 (Print Publication: 2016).Publisher: African Field Epidemiology Network Country of Publication: Uganda NLM ID: 101517926 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

Subcutaneous administration of infliximab-attenuated silica-induced lung fibrosis.

• Authors : Zhang H; Qilu Hospital of Shandong University, Jinan, China (Department of Respiratory Medicine). .; Sui JN

Subjects: Silicon Dioxide*; Infliximab/Infliximab/Infliximab/*pharmacology ; Pulmonary Fibrosis/Pulmonary Fibrosis/Pulmonary Fibrosis/*prevention & control

• Source: International journal of occupational medicine and environmental health [Int J Occup Med Environ Health] 2018 Jul 04; Vol. 31 (4), pp. 503-515. Date of Electronic Publication: 2017Publisher: Nofer Institute of Occupational Medicine Country of Publication: Poland NLM ID: 9437093 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان